Navigation Links
Lo studio EXAMINE della Takeda sulla sicurezza cardiovascolare di alogliptin in aggiunta alla terapia standard ha soddisfatto l'endpoint primario di non inferiorità rispetto al placebo dimostrando che non si verifica nessun incremento del rischio ca
Date:9/17/2013

ia, pancreatite, tumori maligni e i risultati degli esami di laboratorio. I tassi di ipoglicemia, tumore maligno, pancreatite, dialisi e un innalzamento dell'amino-transferasi sierica sono stati simili per i gruppi alogliptin e placebo. Nel corso dello studio non sono stati riportati casi di cancro del pancreas. I gruppi alogliptin e placebo non hanno evidenziato differenze significative relativamente ai tassi degli eventi avversi seri (rispettivamente 33,6% e 35,5%, p=0,14).

Informazioni su EXAMINE
EXAMINE , uno studio clinico globale, di grandi dimensioni, randomizzato, in doppio cieco, controllato con placebo, è stato concepito per valutare la sicurezza cardiovascolare del trattamento con alogliptin in aggiunta al trattamento standard, in confronto al placebo in aggiunta al trattamento standard solamente, in pazienti affetti da diabete di tipo 2 e una sindrome coronarica acuta (ACS) recente (da 15 a 90 giorni prima della randomizzazione). Lo studio aveva un endpoint primario composito di morti per cause cardiovascolari, infarto miocardico non fatale e ictus non fatale.

Nel gruppo trattato con alogliptin, il 71,4% dei pazienti è stato trattato con 25 mg, il 25,7% con 12,5 mg, e il 2,9% con 6,25 mg di alogliptin al giorno. I dosaggi di alogliptin sono stati determinati in base alla funzionalità renale: tasso di filtrazione glomerulare stimato (eGFR) secondo la formula della "Modification in Diet in Renal Disease" > 60 ml/min, 25 mg giornalieri; < 60 ml/min ma > 30 ml/min, 12,5 mg giornalieri; e < 30 ml/min, 6,25 mg giornalieri. L'interruzione prematura del farmaco in studio è stata simile nei gruppi alogliptin e placebo (20,9% dei pazienti rispetto a 22,6%). La durata mediana dell'esposizione al farmaco in studio è stata di 533 giorni (range interquartile, 280 - 751 giorni). Al termine dello studio, la variazione media di HbA1c dal basale è stata pari a -0,33% e 0,03% rispettivamente nel gr
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Anthony Creed Joins DDSTUDIO As GM, Experience Design
2. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
3. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
4. I benefici della tecnologia Hologic per lutilizzo della Tomosintesi in vengono corroborati dalla pubblicazione di uno studio italiano
5. Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2
6. River City Laser Tattoo Removal Studio Offers Grand Opening Discounts on Treatments Using the Astanza Revolution Laser
7. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease
8. New 2012 Cold Chain Report Examines the Extent of Temperature Excursions During the Handling of Temperature-Sensitive Pharmaceutical Shipments
9. Study Examines Smart Pharma Strategies for Effective Messaging around New Products and the Medical Conditions they Treat
10. TeamHealth White Paper Examines Telemedicine Risks, Risk Management Strategies
11. The Food Journal Examines Dietary Supplements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014 Research and ... "Physician Office Laboratory Markets, 3rd Edition" ... report, Physician Office Laboratory Markets is Kalorama,s complete ... industry. Physician office laboratories are diverse in their ... reimbursable, in-office pregnancy and glucose tests. Some specialty ...
(Date:9/23/2014)... , Sept. 23, 2014 This test can detect ... "risk event" is defined by activities that can transfer body ... or use of any shared needles. , An ... oral fluid. This HIV test works by looking for your ... results in 20 minutes, enabling patients to learn their status ...
(Date:9/23/2014)... 2014  Hill-Rom (NYSE: HRC ) today ... Renton, WA ), the nation,s third largest ... existing relationship as Hill-Rom now becomes Providence Health,s sole-source ... frame and surface products. Providence Health ... U.S.  It operates 34 hospitals, 475 physician clinics, 22 ...
Breaking Medicine Technology:Physician Office Laboratory Markets, 3rd Edition 2Physician Office Laboratory Markets, 3rd Edition 3WholeHealth Products announces the release of the FDA Cleared "HIV 1&2" Rapid Diagnostic Test for Professional and Retail 2Hill-Rom Announces Seven-Year, Sole-Source Contract with Providence Health 2
... (NASDAQ: SIAL ) today announced that its ... ), is introducing a novel CHOZN® GS-/- Zinc Finger ... for use in the production of biopharmaceuticals, the new ... glutamine synthetase (GS) knockout CHO cell line proven to ...
... LAS VEGAS, Oct. 26, 2011 Clinical Research Management, ... basic and applied research, clinical trials, and regulatory support, ... Boyer, Ph.D., will co-present a panel titled Battle ... the MAGI West Clinical Research Conference, October 23-26, 2011 ...
Cached Medicine Technology:SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 2SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 3SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 4ClinicalRM to Co-Present Regulatory Compliance Panel at MAGI 2
(Date:9/23/2014)... As a consumer in today’s world, precautionary measures ... to trust testimonials that are supplied by the merchants ... customers into saying anything. , Consumer advocacy groups aim ... in depth coverage on a particular market i.e. nutrition. ... this issue and focus on exposing the thousands of ...
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 (HealthDay ... breast milk is more likely than a blood transfusion to ... a new study finds. The researchers evaluated more than ... weighed 3.3 pounds or less and many who were born ... whether breast milk or transfusions carried the bigger risk. Infants ...
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- A test used to diagnose ... where certain lung infections are more common, a new analysis ... is through the use of what,s known as functional imaging. ... FDG-PET is used, according to the study authors. Cancerous ... parts of the lungs that don,t have cancer, according ...
(Date:9/23/2014)... Genomic medicine is rapidly developing, bringing with its ... and optimize prevention and treatment interventions. Genetic ... immunodeficiency virus (HIV) and hepatitis c virus (HPC), ... be used to screen for an individual,s susceptibility ... treatments for addiction. , While there appear to ...
(Date:9/23/2014)... DC (PRWEB) September 23, 2014 ... care? The National Quality Forum (NQF) released ... ( http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=77687 ), and an infographic ( http://bit.ly/1tX3lzA ... rising cost of healthcare, how patients define affordability, ... consumers to get the best possible healthcare at ...
Breaking Medicine News(10 mins):Health News:Consumer Health Reports Debuts Revolutionary Review Website 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:NYU-Mount Sinai Beth Israel study explores drug users' opinions on genetic testing 2Health News:Finding Affordable Care: Asking the Right Question is Key 2
... Enables PHNS and Healthcare Organizations to Audit, Enforce ... ... Regulations, BATON ROUGE, La., Nov. 16 TraceSecurity, a leading,provider ... its web-based Compliance Manager available to,hundreds of healthcare organizations across the ...
... to Improved HIV Management in Developing World, UPPSALA, ... has signed an agreement with a consortium of American ... of operational,funding, and has committed to raising additional funding ... Cavidi,s newly adopted three-year,business plan. Cavidi is the producer ...
... Agreement Ends Dispute Regarding Fee Disclosures for Separate ... ULLICO Inc. announced an,agreement resolving a Department of ... the Employee Retirement Income Security,Act of 1974 (ERISA). ... began as an inquiry,into ULLICO,s pension plan, ultimately ...
... Human Sexuality, Discussion on the Major Trends in Human Sexual Behavior, Sexual Desire, ... Sexual Dysfunction Issues, NEW YORK, Nov. 16 , WHAT: Are medicine and ... lead to better sex lives? What role does sex play in the ... and other compelling issues on human sexuality ...
... 16 HealthPartners,is the top-performing health plan in the ... newly released business report. The report, sponsored by the,National ... request for,information tool. The tool is used by purchasers ... Health Care Action Group, a coalition of,private and public ...
... November 15 - December 31, TULSA, Okla., Nov. ... today that it will offer three Medicare Part D,prescription ... eligible for Medicare. Medicare beneficiaries in Oklahoma can sign,up ... during the 2008,annual open enrollment period, which begins November ...
Cached Medicine News:Health News:TraceSecurity Announces Partnership with PHNS Expanding Compliance Services to Hundreds of Healthcare Systems 2Health News:TraceSecurity Announces Partnership with PHNS Expanding Compliance Services to Hundreds of Healthcare Systems 3Health News:New Investors Fund Expansion of Cavidi AB 2Health News:ULLICO Inc. and U.S. Department of Labor Agree to Resolve 5 Year Old ERISA Investigation 2Health News:ULLICO Inc. and U.S. Department of Labor Agree to Resolve 5 Year Old ERISA Investigation 3Health News:Charlie Rose Science Series 2Health News:HealthPartners is National Benchmark in Six Out of Seven Areas in National Business Coalition on Health Report 2Health News:Blue Cross and Blue Shield of Oklahoma Announces Flexible, Affordable Blue MedicareRx(SM) Medicare Prescription Drug Plans 2
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique to be used in left hand. Round knurled handle....
6 mm curved hook. Flat serrated handle with polished finish. Overall length: 4.7 inches. Most popular size or model....
Small bulbous tip with flat sides. Flat serrated handle with polished finish. Overall length: 5.1 inches....
7 mm flattened hook. Flat serrated handle with polished finish. Overall length: 4.9 inches....
Medicine Products: